A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 06 Nov 2018 Planned End Date changed from 31 Mar 2022 to 1 Feb 2021.
- 12 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2018 Planned initiation date changed from 30 Apr 2018 to 5 Apr 2018.